Schering-Plough/Merck File Claritin, Singulair Combination
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA has been accepted by FDA for a standard 10-month review.
You may also be interested in...
Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.